相关实验视频

Updated: Jun 5, 2025

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Combination of High Ligation and Intraoperative Embolization using Polidocanol for Treatment of Varicoceles

Published on: December 22, 2023

使用聚多卡诺尔内静脉微泡进行血管内凝血管理的早期经验:风险因素分析

Mariam Mesa-Damiano¹, Francisco J Melesio¹, Jailenne I Quiñones-Rodriguez¹

¹Department of Clinical Anatomy, Sam Houston State University College of Osteopathic Medicine, Conroe, TX, USA.

|December 16, 2024

概括

较低的聚多卡诺尔静脉内微泡 (PEM) 注射量与患血管内凝血 (IC) 的风险更高有关. 需要进一步的研究来确定静脉治疗的最佳PEM注射量.

科学领域:

血管外科血管外科
弗莱博学 (Phlebology) 是一种神经病学.
医疗器械研究医疗器械研究

背景情况:

血管内凝血 (IC) 是一种在临床实践中观察到的并发症,在治疗慢性静脉功能不全时使用聚多卡诺尔内静脉微泡 (PEM) 治疗后出现.
识别IC的风险因素对于改善患者的治疗结果和治疗方案至关重要.

研究的目的:

为了调查与治疗后的血管内凝血 (IC) 的发展相关的潜在风险因素,polidocanol内静脉微泡 (PEM).
分析患者的人口统计,并发病症和超声检查结果与IC发病率相关的数据.

主要方法:

一项对119名因慢性静脉功能不全而接受PEM治疗的患者进行的回顾性队列研究.
根据临床表现和超声波确认的凝血吸血,患者被分为IC (n=16) 和非IC (n=103) 组.
分析了人口统计数据,并发症和双重超声报告.

主要成果:

总的来说,13%的患者发展了IC,平均发病时间为45天.
单变量分析表明,较低的PEM注射量,高的大沙静脉 (GSV) 反流以及拉丁裔种族是潜在的风险因素.
多变量分析证实较低的PEM注射量是IC发展的唯一显著风险因素 (p=0.006).

结论:

较低的polidocanol静脉内微泡注射量代表了血管内凝血形成的显著风险因素.
需要进行进一步的研究,以确定每个治疗静脉段的理想注射量,以减轻IC风险.

关键词:

血管内凝结体血管内凝结体聚多卡诺尔内静脉微泡是一种内静脉微泡.有关风险因素的风险因素.硬化疗法是一种硬化疗法.

更多相关视频

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Occlusion of the Great and Small Saphenous Vein Using Copolymeric Glue Based on N-Butyl Cyanoacrylate and Methacryloxy Sulfolane

Published on: December 9, 2022

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.